The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Design and Analysis of Phase I Clinical Trials
Abstract
The Phase I clinical trial is a study intended to estimate the so-called maximum tolerable dose (MTD) of a new drug. Although there exists more or less a standard type of design for such trials, its development has been largely ad hoc. As usually implemented, the trial design has no intrinsic property that provides a generally satisfactory basis for estimation of the MTD. In this paper, the standard design and several simple alternatives are compared with regard to the conservativeness of the design and with regard to point and interval estimation of an MTD (33rd percentile) with small sample sizes. Using a Markov chain representation, we found several designs to be nearly as conservative as the standard design in terms of the proportion of patients entered at higher dose levels. In Monte Carlo simulations, two two-stage designs are found to provide reduced bias in maximum likelihood estimation of the MTD in less than ideal dose-response settings. Of the three methods considered for determining confidence intervals--the delta method, a method based on Fieller's theorem, and a likelihood ratio method--none was able to provide both usefully narrow intervals and coverage probabilities close to nominal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Stochastic Approximation Method
Robbins, H., & Monro, S. (1951) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729586 · Cited by 9,643
Statistical Method in Biological Assay.
Healy, M. J. R., & Finney, D. J. (1979) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2982559 · Cited by 3,586
SEQUENTIAL ESTIMATION OF POINTS ON A PSYCHOMETRIC FUNCTION
Wetherill, G. B., & Levitt, H. (1965) · British Journal of Mathematical and Statistical Psychology · doi:10.1111/j.2044-8317.1965.tb00689.x · Cited by 1,196
Sequential Estimation of Quantal Response Curves
Wetherill, G. B. (1963) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1963.tb00481.x · Cited by 263
Efficient Sequential Designs with Binary Data
Wu, C. F. J. (1985) · Journal of the American Statistical Association · doi:10.1080/01621459.1985.10478213 · Cited by 206
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
Goldsmith, M. A., Slavik, M., & Carter, S. K. (1975) · PubMed · Cited by 134
Interval Estimation of the Median Lethal Dose
Williams, D. A. (1986) · Biometrics · doi:10.2307/2531213 · Cited by 87
Design of Phase I and II Clinical Trials in Cancer: A Statistician's View
Geller, N. L. (1984) · Cancer Investigation · doi:10.3109/07357908409048522 · Cited by 61
Mouse to man: statistical problems in bringing a drug to clinical trial
Schneiderman, M. A. (1967) · Project Euclid (Cornell University) · Cited by 35
Cited by
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 472
Metadata
- Authors
- Storer, B. E.
- Venue
- Biometrics
- Publisher
- JSTOR
- Published
- 1989-09
- Volume
- 45
- Issue
- 3
- Pages
- 925
- ISSN
- 0006-341X (ISSN-L)
- OpenAlex
- W2054383376
- Cited by
- 930
- References
- 9
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.